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Receptor functionPost-translational modiﬁcation by the SUMOmoiety is now regarded as one of the key regulatory modiﬁcations
in eukaryotic cells. Up to now, plenty of sumoylated proteins have been found to be involved in nuclear processes
such as chromatin organization, transcription and DNA repair as well as in other cellular functions. Since the
number of data concerning sumoylated proteins and their function outside the nucleus has grown rapidly, in
this review we summarized the results describing the non-nuclear role of SUMO substrates. In particular, we
focused on the role of sumoylation in the regulation of channel activity, receptor function, G-protein signaling,
activity of enzymes, cytoskeletal organization, exocytosis, autophagy and mitochondrial dynamics.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Sumoylation belongs to the same group of post-translational
modiﬁcations as ubiquitination and neddylation [1] and involves the
attachment of SUMO (small ubiquitin related modiﬁer) molecule to
the target protein through isopeptide bond formation. The SUMO
protein, having a molecular mass of about 11 kDa, is highly conserved
from yeast to humans [2]. There are four SUMO molecules, SUMO-1,
SUMO-2, SUMO-3 and SUMO-4. SUMO-2 shares 95% identity in amino
acid sequence with SUMO-3 and they are often referred to as SUMO-
2/3. Presently, SUMO-2 and SUMO-3 cannot be distinguished by
antibodies. SUMO-2/3 contains a ﬂexible N-terminus, which seems to
serve as an acceptor in SUMO chain formation [3]. The shared identity
in amino acid sequence between SUMO-2/3 and SUMO-1 is ~45%. Inter-
estingly, SUMO-1 shares ~18% identity with ubiquitin and has a similart serine protein kinase; COS-7,
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8 22 822 53 42.three-dimensional structure that is characterized by a globular β-grasp
fold [4]. Quantitative andqualitative analyses of SUMO-1 and SUMO-2/3
in vertebrate cells have shown that the amount of SUMO-2/3-modiﬁed
targets is greater than the amount of SUMO-1 modiﬁed proteins [5].
Both SUMO-2/3 and SUMO-1 contain the C-terminal Gly-Gly motif
which is exposed to proteolytic cleavage during the process of matura-
tion. This motif is crucial in the isopeptide bond formation occurring
between the SUMO and a lysine side chain of the target protein [6].
SUMO-4 is similar to SUMO-2/3 and its maturation might be inhibited
by a unique proline residue located at position 90 [7]. Also, it is known
that the SUMO-4 precursor can be cleaved by the stress-induced endog-
enous hydrolase which, in consequence, facilitates its attachment to
target proteins [8].
Usually, SUMO is attached to a lysine residue located in the consen-
sus sequence ψKxD/E, where ψ corresponds to a large hydrophobic
amino acid, K is a lysine residue, x is any amino acid, E is a glutamic
acid and D is an aspartic acid [9]. Presently some additional motifs re-
sponsible for SUMO attachment are known [10]. Interestingly, detailed
analysis of many SUMO substrates has shown that E is preferred
over D in the consensus motif [11]. It should be also mentioned that
inmany casesmodiﬁcation by SUMOmight occur at lysine residues out-
side the consensusmotif. The sumoylation process is catalyzed by three
groups of enzymes: E1-activating enzyme, E2-conjugating enzyme and
E3-ligases (Fig. 1). SUMO attachment proceeds as follows. E1 SUMO
enzyme activates the SUMO C-terminus in an ATP-dependent manner
and carries out the transfer of activated SUMO to E2 SUMO-conjugating
enzyme. Next SUMO is transferred from E2 to the substrate with the as-
sistance of one of several SUMO-protein ligases (E3s). The speciﬁcity of
the reaction is related to the activity of E2 and E3 enzymes [12]. While
there is a variety of E3-ligases, only one E1 activating enzyme (SAE1/2)
Fig. 1. A scheme illustrating the sumoylation process. E1, E2 and E3: enzymes involved in SUMO attachment to target proteins, SENP: SUMO-deconjugating enzyme.
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catalyzes SUMO attachment, E3 ligases play an important regulatory
role since they increase sumoylation efﬁciency and determine substrate
speciﬁcity. SUMOE3 ligaseswith a RING-ﬁnger like domain belong to the
family of SP-RING-containing proteins. This family is represented by PIAS
(protein inhibitor of activated STAT) family proteins (PIAS1, PIAS3,
PIASxα, PIASxβ and PIASy) in vertebrates and the Siz family proteins
(Siz1 and Siz2) in Saccharomyces cerevisiae [13]. Another SUMO E3 ligase
containing a domain distinct from the canonical RING type is RanBP2 [14].
Several other proteins have been also reported as E3 ligases. This group
includes human polycomb 2 homologue (PC2) [15], histone deacetylase
4 (HDAC4) [16], topoisomerase I-binding RING ﬁnger protein (TOPORS)
[17] and Ras homologue enriched in striatum (RHES) [18].
Sumoylation is a reversible modiﬁcation. Detachment of SUMO
is catalyzed by SUMO proteases, SENPs, also known as desumoylating
enzymes. In mammalian tissues six such proteases have been
described: SENP1–3 and SENP5–7. Among the SENP family, SENP1
and SENP2 show speciﬁcity toward SUMO-1 and SUMO-2/3 while
SENP3 and SENP5–7 toward SUMO-2/3 [19,20]. Quite recently three
other desumoylating enzymes have been found. These are DeSI1
(desumoylating isopeptidase 1), DeSI2 (desumoylating isopeptidase
2) and USPL1 (ubiquitin-speciﬁc protease-like 1) [21,22].
Sumoylation regulates many cellular functions, mainly by inﬂuenc-
ing protein–protein interactions [23]. SUMO attachment can mask
protein–protein interaction sites, create a new binding interface or
lead to conformational changes. The involvement of SUMO in the regu-
lation of protein–protein interaction is often linkedwith the presence of
a motif called SIM (Sumo Interacting Motif), that facilitates recognition
of sumoylated proteins. The best characterized class of SIMs consists of a
hydrophobic core ([V/I]-x-[V/I]-[V/I]) ﬂanked by a cluster of negatively
charged amino acids [24,25]. Interestingly, proteins undergoing
sumoylation often bear SIM in their structure which allows them to
form multiple protein complexes. To monitor protein–protein interac-
tion/formation of complexes in vivo, the trans-SUMOylation assay has
been elaborated [26]. Brieﬂy, Ubc9 is fused with the protein of interest,
protein 1. Upon interaction of protein 1with the co-expressed protein 2,
Ubc9 induces trans-SUMOylation of protein 2 which is manifested
by a shift in its electrophoretic mobility. The trans-SUMOylation assay
facilitates studies on protein–protein interactions at a level similar to
that observed for endogenous proteins.The very ﬁrst protein described as a substrate of SUMO was
RanGAP1 [27,28]. Up to now a lot of proteins that play a pivotal role in
transcription, chromatin organization, DNA repair, telomere mainte-
nance, nucleocytoplasmic transport, protein degradation or cell cycle
regulation have been found to be modiﬁed by the SUMO molecule [2,
29–35]. It is well known that sumoylation might induce nuclear import
of certain proteins [36]. There are some hints that nuclear export might
be regulated in the same way [37,38]. Interestingly, apart from results
concerning function of sumoylated proteins in the nucleus new exciting
data about the role of SUMO substrates outside the nucleus have
emerged recently [39]. At present it might be difﬁcult to reconcile
these ﬁndings with the common notion, substantiated by experimental
data, that the enzymes responsible for sumoylation and desumoylation
are enriched in the nucleus. However, there are results showing the
presence of E1 and E2 in the cytoplasm of HeLa cells [36], E2 (Ubc9) in
the endoplasmic reticulum [40] and SENP5 in the mitochondria [41].
Furthermore, it has been shown that the sumoylating enzymes operate
at the cytoplasmic ﬁlaments of the nuclear pore complex [36] where
they may contact/sumoylate cytoplasmic proteins. Thus, although how
it occurs is not yet clear, the sumoylation of non-nuclear proteins is a
fact well established.
The majority of data on non-nuclear SUMO targets concern the role
of sumoylation in neuronal function [42–46]. It has been shown that
sumoylation inﬂuences various aspects of neuronal activity including
excitability or synaptic transmission [47–50]. The list of non-nuclear
proteins whose function depends on sumoylation is very long [51],
thus the present review is focused on the SUMO substrates for which
the functional effect of sumoylation is quite well established (Table 1).
In particular we describe, and illustrate in Fig. 2, the inﬂuence of protein
sumoylation on channel activity, receptor function, G-protein signaling,
enzyme activity, cytoskeletal organization, exocytosis, autophagy and
mitochondrial dynamics.
2. Channel activity
Potassium selective, plasma membrane leak channels K2P, are
known to control neuronal excitability [52]. Onemember of this family,
K2P1, is sumoylated on lysine 274 which does not belong to a classical
consensus motif. Interestingly, the SUMO-conjugating enzyme, Ubc9,
has been found to associate with K2P1 in the plasma membrane. Also,
Table 1
The list of SUMO substrates acting outside the nucleus.
Non-nuclear protein Reference
K2P1 [47,53]
Kv1.5 [56]
Kv2.1 [57]
TRPM4 [59]
mGluR4 [62]
mGluR6–8 [63,64]
GluK2 [69–71]
TβRI [74]
RGSZ1, RGSZ2 [76]
Phosducin [79]
Caveolin-3 [80]
CASK [50]
FAK [83]
PTP1B [86]
La protein [49]
Rac1 [92]
RhoGDI [93,94]
CacyBP/SIP [99]
hnRNPA2B1 [102]
RIM [106]
Vps34 [110]
p53 [117,118]
Drp1 [120–124]
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K2P1 while removal of this moiety recovered its function [47]. Opposite
data have been obtained by the group of Feliciangeli [53]. These authors
have shown that K2P1 is not quantitatively sumoylated in COS-7 cells
and in Xenopus oocytes. Also, it has been postulated that modiﬁcation
of lysine 274 by SUMO is not important for silencing K2P1 activity [53].
Thus to elucidate the role of K2P1 sumoylation experiments with
the use of K2P1 single-particle ﬂuorescent microscopy have been
performed. The results have shown that each K2P1 subunit provides a
single SUMO conjugation site and that one SUMO moiety is able to si-
lence the activity of channels composed of K2P1 and other K2P subunits
[54]. Thus, results concerning K2P1 might suggest that sumoylation
controls the function of ion channels.
Potassium voltage-gated channels, Kv, are integral membrane pro-
teins that allow diffusion of K+ across the plasmamembrane according
to its electrochemical gradient. Kv channels represent the largest and
most diverse channel family. They are divided into twelve subfamilies,
Kv1–Kv12. A functional Kv channel is composed of four subunits each
of which has six transmembrane segments [55]. The Kv1–Kv4 subfam-
ilies are most widely expressed in the central nervous system. Two
channels belonging to Kv1–Kv4 are described below. Kv1.5 is a neuro-
nal K+ channel containing two membrane-proximal and highly
conserved cytoplasmic sequences undergoing modiﬁcation by SUMO.
Desumoylation of this channel is catalyzed, in vivo and in vitro, by
SUMO-speciﬁc protease SENP2. Detachment of SUMO from Kv1.5,
either by disruption of the conjugation sites or expression of the
SUMO protease SENP2, leads to a hyperpolarizing shift in the voltage-
dependence of steady-state inactivation [56]. Kv2.1 is a potassium
channel important in the brain for determining activity-dependent
excitability. Similar to the case of Kv1.5, sumoylation/desumoylation
of Kv2.1 in hippocampal neurons alters the biophysical parameters of
this channel and modiﬁes its activity [57].
TRPM4 (transient receptor potential melastatin 4), a voltage-
dependent, nonselective cation channel is impermeable to Ca2+. It is ac-
tivated by elevation of intracellular Ca2+ concentration and modulated
by ATP [58]. A missense G19→Amutation in the gene encoding TRPM4
is linked to the progressive familial heart block type I (PFHBI) disease.
Cellular expression studies have shown that the mutated form of
TRPM4 channel does not undergo desumoylation. The permanently
sumoylated formof TRPM4mutantwas associatedwith impaired endo-
cytosis. Thus, sumoylation of the TRPM4 channel seems to be involved
in the development of PFHBI disease [59].3. Receptor function
G-protein-coupled (metabotropic) receptors, mGluRs, based on
sequence homology, agonist speciﬁcity and association with second
messengers, are subdivided into three groups [60,61]. Using a bacterial
sumoylation assay, it has been shown that members of group III,
mGluR4 and mGluR6–8, can be modiﬁed in vitro by SUMO [62]. It is
well known that mGluR8 plays a key role in regulating pre-synaptic ac-
tivity through G-protein-dependent signaling pathways and through
intracellular protein–protein interactions, however the exact role of
mGluR8 sumoylation has not been established [63,64].
Ion-channel-associated (ionotropic) receptors, based on their ago-
nists, are divided into three families: NMDARs (N-methyl-D-aspartate),
AMPARs (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid)
and KARs (kainate receptors) [65]. Kainate receptors (KARs) are ubiqui-
tous in the adult nervous system [66] and play a role in modulating
synaptic transmission and plasticity, particularly in the hippocampus.
KARs are tetrameric combinations of ﬁve different subunits: GluK1,
GluK2, GluK3, GluK4 or Gluk5 [67]. It has been found that one of these
subunits, GluK2, undergoes sumoylation. Under resting conditions
there is a low level of sumoylated GluK2 while in response to kainate
treatment the amount of SUMO covalently bound to GluK2 markedly
increases. It has been found that reduction of GluK2 sumoylation by a
desumoylating enzyme, SENP1, prevents kainate-evoked endocytosis
of KARs. Moreover, a mutated, non-sumoylatable form of GluK2 was
not endocytosed in response to kainate [48]. Thus, modiﬁcation of
GluK2 by SUMO attachment regulates endocytosis of KARs and might
modify synaptic transmission. Studies performed onGluK2 sumoylation
have revealed involvement of this modiﬁcation in ischemic neuro-
toxicity through the inﬂuence on MLK3 (mixed lineage kinase 3) and
JNK (c-Jun N-terminal kinase) activity. The MLK3 kinase functions as
an upstream initiator of JNK3 signaling cascades [68,69]. After ischemia,
activated MLK3 kinase binds and activates MAPK4 and MAPK7, which
in turn phosphorylate and activate JNK3. Interestingly, sumoylation of
GluK2 inﬂuences the activity of MLK3 and JNK3 after kainate stimula-
tion. It has been shown that overexpression of wild-type GluK2, but
not that of its sumoylation-deﬁcient mutant, causes an increase in
the activity of MLK3 and JNK3. Simultaneously, sumoylation deﬁciency
attenuates the kainate-stimulated interaction between MLK3 and
GluK2. In addition, inhibition of kainate-evoked GluK2 endocytosis
attenuates MLK3–JNK3 signaling and the binding between MLK3 and
GluK2 in cultured cortical neurons. These results suggest that internali-
zation of GluK2 following SUMO attachment promotes its binding to
MLK3, activates the MLK3–JNK3 pathway and, in consequence, causes
ischemic neuronal cell death. Sumoylation of GluK2 occurs on lysine
886 and is promoted by PKC-mediated phosphorylation of serine 868.
Interestingly, serine 868 is relatively far away from lysine 886 in
comparison to other substrates the sumoylation of which depends on
phosphorylation. Both sumoylation and phosphorylation of GluK2 are
responsible for internalization of GluK2-containing KARs that occurs
during long-term depression of KAR-mediated synaptic transmission.
Conversely, phosphorylation of GluK2 on serine 868 in the absence
of sumoylation leads to an increase in KARs surface expression by facil-
itating receptor recycling between endosomal compartments and the
plasma membrane [70,71].
Transforming growth factor receptors β, TβRI and TβRII, are trans-
membrane proteins. Both have serine/threonine kinase activity and
formheteromeric complexes upon activation/binding of TGF-β. Binding
of TGF-β to TβRII leads to the recruitment of TβRI, activation of TβR1 ki-
nase and, ﬁnally, activation of Smad2 and Smad3 [72,73]. Interestingly,
it has been reported that in response to TGF-β stimulation, TβRI is
sumoylated on lysine 389 located in a non-consensus sumoylation
site. Sumoylation of the TβRI receptor enhances the recruitment and
phosphorylation/activation of Smad2 and Smad3 and, in consequence,
regulates TGF-β induced transcription. Moreover, in Ras-transformed
cells, TβRI sumoylation contributes to tumor progression [74].
Fig. 2. Schematic illustration of the role of SUMO attachment to proteins functioning outside the nucleus. Role of sumoylation in (A) channel activity, (B) receptor function, (C) G-protein
signaling, (D) enzyme activity, (E) cytoskeletal functions, (F) exocytosis, (G) autophagy, and (H) mitochondrial dynamics. Detailed description of particular schemes is within the text.
α,β,γ— subunits of G protein; Ac, acetyl group; ER, endoplasmic reticulum; Src, protein tyrosine kinase; x (red)— inhibition of transport or activity;ΔΨ— change inmembrane potential;
• — neurotransmitter.
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The RGSZ1 and RGSZ2 proteins are regulators of the G-protein
coupled receptors. The expression of RGSZ1 and RGSZ2 is tissue-
speciﬁc and restricted to the nervous system. Both proteins play a role
in μ-opioid receptor desensitization [75]. In synaptosomal membranes,
RGSZ1 and RGSZ2 undergo post-translational modiﬁcations such as gly-
cosylation and phosphorylation. Also, it has been reported that these
proteins might be modiﬁed by SUMO. RGSZ1 exists in a sumoylated
and non-sumoylated form while the majority of RGSZ2 is conjugated
to SUMO. Sumoylation of RGSZ1 and RGSZ2 occurs during μ-opioid re-
ceptor activation and facilitates interactions with this receptor. Such
an effectwas not observed in the case of δ-opioid receptors. To elucidate
the role of RGSZ1 and RGSZ2 sumoylation, interaction of these proteins
with Gαi2 and Gαz subunits was examined. It has been found that Gαi2
and Gαz co-immunoprecipitate with sumoylated RGSZ1 and, to amuch
lesser extent, with its non-sumoylated form. Thus, sumoylation of
RGSZ1 and RGSZ2 might enhance their binding to Gα subunits and
mediate desensitization of the G-protein coupled receptor [76].G-protein regulator, phosducin, is a 33-kDa cytosolic protein, ﬁrst
described as an abundant phosphorylated protein in the mammalian
retina [77]. Later, it has been shown that this protein is ubiquitously
expressed in pineal gland and several other tissues. Phosducin acts as
a regulator of G-protein-coupled signal transduction via binding with
high afﬁnity to the βγ subunits of heterotrimeric G-proteins (Gβγ).
Tight binding of phosducin to βγ subunits sequesters them in the cyto-
sol which prevents their reassociation with the α subunit and impedes
signal ampliﬁcation [78]. It has been shown that phosducin contains
a consensus motif for sumoylation and that lysine 33 within this motif
is a SUMO acceptor [79]. Sumoylation of phosducin, similarly to
phosphorylation, decreases its interaction with the Gβγ subunits. Also,
sumoylation of phosducin protects this protein from proteasomal
degradation.
Caveolin-3 is another protein, the sumoylation ofwhich is important
for regulation of G-protein coupled receptors. Caveolin-3, an integral
membrane protein, serves as an important structural and regulatory
component of caveolae membranes. Modiﬁcation of caveolin-3 by
sumoylation occurs in the presence of PIASy E3 ligase and seems to
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caveolin-3 regulates the level of the aforementioned receptor has not
been established.
5. Enzyme activity
There are quite a number of enzymes that undergo sumoylation.
Most of them are described in the context of nuclear function. Below
we list the enzymes in which modiﬁcation by SUMO is important for
non-nuclear function.
Calcium/calmodulin-dependent serine protein kinase, CASK, be-
longs to the membrane-associated guanylate kinase (MAGUK) family
of scaffolding molecules that are associated with intercellular junctions
[81]. CASK interacts with postsynaptic transmembrane proteins which
are involved in synaptogenesis. Among them is protein 4.1. It has
been shown that CASK sumoylation reduces its interactionwith protein
4.1. Since it has been postulated that CASK acts as a linker between
transmembrane proteins and the actin cytoskeleton, attachment of
SUMO to CASK might be involved in the regulation of dendritic spine
formation. Overexpressed CASK–SUMO localizes at synapses but not
in the synaptic membrane [50].
Focal adhesion kinase, FAK, is a protein tyrosine kinase regulating cy-
toskeletal structures and cell adhesion [82]. FAK undergoes sumoylation
at a conserved lysine residue at position 152. Attachment of SUMO to
FAK increases its autophosphorylation, interaction with Src kinase and,
ﬁnally, its activity [83].
Protein-tyrosine phosphatase 1B, PTP1B, is an endoplasmic
reticulum-associated protein phosphatase highly expressed in the
brain [84]. It has been shown that PTP1B is involved in the regulation
of growth-factor signaling and cell proliferation by binding to receptor
tyrosine kinases, such as the insulin receptor [85]. Studies concerning
regulation of PTP1B cellular function led to the identiﬁcation of PTP1B
sumoylation by SUMO ligase, PIAS1, in mammalian ﬁbroblasts [86].
Sumoylation of PTP1B phosphatase has been shown to inhibit the
negative effect of this enzyme on insulin receptor signaling and on cell
transformation. Simultaneously, insulin-stimulated sumoylation inﬂu-
ences PTP1B stability, and ﬁnally causes a transient down regulation of
the enzyme. Since, in the brain, PTP1B is involved in leptin signaling,
sumoylation of this phosphatase might also regulate this pathway [87].
6. Cytoskeletal functions
Cytoskeletal function of the La protein is related to its interactionwith
motor proteins. It has been shown that La is involved in local protein
synthesis in axons and in binding of multiple axonal mRNAs [88,89].
Sumoylation of La on lysine 41 increases its binding to dynein whereasFig. 3. Involvement of sumoylated protdesumoylation promotes its interaction with kinesin. Sumoylation of La
is also required for retrograde transport. SUMO-defective mutant of
La inwhich lysine 41was replaced by arginine shows anterograde trans-
port while thewild type protein exhibits bidirectional transport in axons
[49].
The Rac1 protein regulates actin cytoskeleton [90,91]. A link be-
tween Rac1, actin cytoskeleton and cell motility has been revealed by
ﬁnding that Rac1 is sumoylated. It has been reported that interaction
of Rac1with SUMO ligase, PIAS3, leads to Rac1 activation and to optimal
cell migration in response to hepatocyte growth factor, HGF. Rac1
sumoylation is also important for maintaining an appropriate level of
Rac1-GTP in the cell and for the ability of Rac1 to stimulate lamellipodia
formation [92]. Not only Rho GTPases but also their protein inhibitors
are important for cytoskeletal function. Binding of Rho GDP dissociation
inhibitor, RhoGDI, to GTPases keeps them in a biologically inactive state
in the cytoplasm, which in consequence has an effect on actin polymer-
ization, cytoskeleton formation and cell motility. It has been reported
that RhoGDI undergoes sumoylation on lysine 138 and that this modiﬁ-
cation, which depends on the XIAP protein (X-linked inhibitor of
apoptosis protein), increases afﬁnity of RhoGDI for small Rho GTPases
[93,94].
Quite recently, the CacyBP/SIP protein has been suggested to play a
role in the regulation of cytoskeleton [95,96]. Besides this function
CacyBP/SIP exhibits phosphatase activity toward ERK1/2 and tau [97,
98]. It has been shown that CacyBP/SIP undergoes sumoylation on lysine
16 located outside the consensus sumoylation motif [99]. Sumoylation
of CacyBP/SIP does not seem to regulate the phosphatase activity. How-
ever, since CacyBP/SIP interacts with cytoskeletal components and
other multiprotein complexes such as the ubiquitin ligase complex,
SUMO modiﬁcation might regulate binding of CacyBP/SIP with compo-
nents of the abovementioned complexes.7. Exocytosis
Exosomes are membrane vesicles released into the extracellular
environment by most cells. Among other components, these vesicles
contain RNAs (mRNAs, miRNAs and other non-coding RNAs) and trans-
port these RNAs to the recipient cells [100,101].
Heterogeneous nuclear ribonucleoproteins, hnRNPs, are a group
of RNA-binding proteins involved in growth regulation. Interaction
between hnRNPA2B1 and miRNAs occurs through miRNA sequences
called EXO-motifs. Recently, it has been reported that sumoylation of
hnRNPA2B1 plays a crucial role in the loading of miRNAs into the
exosomes since application of a sumoylation inhibitor, anacardic
acid, interferes with efﬁcient sorting of hnRNPA2B1 to these vesicles
[102].eins in different cellular processes.
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fusion machinery in synapses [103]. One of these proteins, RIM1α, has
been shown to interact with small GTP binding proteins [104] and to
modulate sequential steps in synaptic vesicle exocytosis by serial pro-
tein–protein interactions [105]. Recently, it has been reported that
RIM1α undergoes sumoylation at lysine 502. Sumoylation of RIM1α en-
ables clustering of Cav2.1 calcium channels and enhances Ca2+ inﬂux
necessary for exocytosiswhile inhibition of RIM1α sumoylation reduces
this effect. Taken together, sumoylation of RIM1α is involved in rapid
and synchronous release of neurotransmitters and seems to act as a
regulator of synaptic vesicle exocytosis [106].
8. Autophagy
Autophagy is a stress-induced, tightly regulated catabolic process
controlling lysosomal degradation of cytoplasmic organelles or other
cellular components [107,108]. Recently, it has been shown that
autophagy evokes an increase in the intracellular level of acetylated, in-
ducible Hsp70. Acetylated Hsp70 interacts with the Vps34–Beclin-1
complex [109]. This causes association of the SUMO ligase, KAP1, with
Vps34 and, in consequence, its sumoylation at lysine 840. Sumoylation
of Vps34 stabilizes its interaction with Beclin-1. Knockdown of Hsp70
inhibits KAP1 binding to Vps34, sumoylation of Vps34 and, in conse-
quence, evokes inhibition of autophagic vesicle formation [110].
Autophagy seems to be also controlled by p53, a protein post-
translationally modiﬁed at multiple sites [111,112]. It has been shown
that together with other modiﬁcations, sumoylation of p53 might
have an impact on its transcriptional activity [113–116]. Moreover, it
has been shown that p53 is sumoylated in the cytoplasmic compart-
ment by a protein complex containing SUMO ligase PIAS4. Sumoylation
of p53 by this complex occurs at lysine 386 and causes an increase in
p53 acetylation at lysine 120. Data have shown that sumoylated and
acetylated p53 is accumulated in the cytoplasm and that these two
modiﬁcations of p53 are crucial for the function of this protein in
controlling autophagy [117,118].
9. Mitochondrial dynamics
The proper balance between ﬁssion and fusion of the mitochondria
is crucial for maintaining cellular homeostasis. The dynamin-related
protein 1, Drp1, is a molecule which controls this balance [119,120].
Drp1 is composed of an N-terminal GTPase domain, that provides the
driving force for mitochondrial membrane constriction. In cytosol,
Drp1 forms soluble dimers and tetramers which are recruited to sites
of mitochondrial division through interactionswith several outermem-
brane proteins [121]. It has been shown that sumoylation of Drp1,
induced by the pro-apoptotic protein Bax, increases its stability and
causes mitochondrial fragmentation in COS-7 cells [120]. In contrast,
desumoylation of Drp1, by overexpression of SENP5 protease, reduces
SUMO-induced mitochondrial fragmentation. On the other hand,
when SENP5 is depleted, mitochondrial fragmentation is increased
[122]. Contradictory results have been obtained by Guo et al. [123].
Using an in vitromodel of ischemia, the authors have shown that deple-
tion of another SUMO protease, SENP3, prolongs sumoylation of Drp1,
which in consequence drives it into the cytoplasm and inhibits
cytochrome c release and caspase-dependent cell death. Depletion of
SENP3 also reduces mitochondrial division. These opposite effects of
Drp1 sumoylation might be due to the fact that SUMO attachment
occurs at multiple sites and that Drp1 is a direct target of sumoylation
by all three SUMO isoforms [124].
10. Conclusions
A lot of data concerning the role of protein sumoylation in the nucleus
have been published but, interestingly, many sumoylated proteins exert
their function outside the nucleus. In this review we have described alarge group of proteins undergoing sumoylation and the impact of this
modiﬁcation on their function in different non-nuclear processes. As
presented, sumoylation may be important in regulating channel activi-
ty, receptor function, G-protein signaling, enzyme activity, cytoskeletal
organization, exocytosis, autophagy and mitochondrial dynamics
(Figs. 2 and 3). This suggests that this proteinmodiﬁcation is omnipres-
ent in cells andmight inﬂuence development of many pathologies such
as neurodegeneration, viral infections or tumorigenesis. Although the
progress in protein sumoylation studies has been impressive there is
still a gap to be ﬁlled by future research. One of the interesting issues
will be to reveal the detailed mechanism and regulation of sumoylation
in order to control this process and design drugs that could be used for
medical purposes.
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